Wells Fargo notes that Vera Therapeutics (VERA) shares are down about 20% today, which the firm attributes to competitor Otsuka saying they will make a prefilled syringe version of the company’s IgAN drug, Sibeprenlimab, available for commercial launch. However, the firm does not see this as a “big threat,” arguing that the pullback in Vera “makes no sense” and should be used as a buying opportunity. Wells maintains an Overweight rating and $70 price target on Vera shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Vera Therapeutics initiated with an Outperform at Wolfe Research
- 3 Best Stocks to Buy Now, 1/29/2025, According to Top Analysts
- Vera Therapeutics initiated with a Buy at Goldman Sachs
- 3 Best Stocks to Buy Now, 1/17/2025, According to Top Analysts
- Vera Therapeutics Highlights Atacicept Progress at Conference
Questions or Comments about the article? Write to editor@tipranks.com